A Suppository Chinese Medicine (Xilei-san) for Refractory Ulcerative Proctitis: A Pilot Clinical Trial

Ken Fukunaga a Nobuyuki Hida a Kunio Ohnishi a Yoshio Ohda a Koji Yoshida a Takeshi Kusaka a Yoshio Jinno a,c Kazuko Nagase a Shiro Nakamura a Muneo Kadobayashi d Hiroto Miwa b Takayuki Matsumoto a

Divisions of a Lower Gastroenterology and b Upper Gastroenterology, Department of Internal Medicine, c Endoscopy Center, and d Department of Pharmacy, Hyogo College of Medicine, Nishinomiya, Japan

Dear Sir,

Six patients with active ulcerative proctitis (UP) (male/female = 2/4) were treated with an originally developed suppository Xilei-san (SXS), a traditional Chinese medicine, which is composed of watermelon frost, calcite, cow gallstone, peel powder, borax, borneol, indigo, and ammonium chloride. This mixed traditional medicine has a long history in China and it has been accepted as a medicine for erosions and ulcerations of the tongue, pharynx and oral cavity. The therapeutic mechanism of XS has never been fully understood, but some domestic reports inform that ulcerative colitis (UC) has been proposed as a possible indication of peroral XS. We have hypothesized that XS might be a useful therapeutic option for active UP patients refractory to conventional topical therapies if it would be applied in suppository form. A prospective open-labeled clinical trial was held from April 1, 2005 to December 31, 2006 to evaluate the efficacy of SXS for active refractory UP patients.

Mean (± SD) age and duration of UP of the enrolled patients were 36.2 ± 9.1 years and 56.3 ± 47.4 months, respectively. All patients had an episode of treatment with a combination of either peroral 5-aminosalicylic acid (5-ASA) or sulphasalazine (SASP) together with conventional suppositories. Eligible patients had a confirmed diagnosis of UP in clinical and endoscopically active relapse although current suppositories had been given for >4 weeks. According to the previous study [1], entry was restricted to patients with disease not extending 15 cm beyond the anus. Patients having any episode of drug allergy and pregnant or lactating women were excluded. SXS was manufactured originally in the pharmacology division of our institute. Our prototype SXS contained 0.1 g/piece of Xilei-San powder (Beijing Tong

Fig. 1. CAI and EI scores were compared before and after the trial. Significant improvements of the mean CAI (4.67 ± 0.82 vs. 1.50 ± 1.52; p < 0.03) and EI (6.67 ± 2.88 vs. 2.17 ± 2.56; p < 0.03) were proven between before and after the trial.
Ren Tang Ltd., Co., Beijing, China) mixed with commercially available carrier glyceride. SXS was given 1 piece/day for 180 days after obtaining sufficient informed consent, and after the local ethics committee had approved a human protocol for this trial. The combined peroral administration was allowed to continue in the same dosage if it had been started >4 weeks before the enrollment. Any combined topical therapy except SXS was never allowed after starting the trial. Clinical and endoscopic efficiencies of SXS were evaluated before and 180 days after beginning the trial utilizing the Rachmilewitz clinical activity index (CAI) and the endoscopic index (EI) [2]. Also, we compared the quality-of-life (QoL) of the patients before and after the trial using an IBDQ [3]. Statistical analysis was made using the Wilcoxon signed-rank test. p < 0.05 was considered statistically significant. Patients tolerated the trial well, and there were no cases either presenting specific adverse reactions or stopping due to deterioration. Their macroscopic bloody feces disappeared in 49.2 ± 25.6 days (range 21–85). Significant improvements of the mean CAI and EI were proven after the trial (fig.1). Also, the mean IBDQ score was improved significantly after the trial (168.8 ± 19.7 vs. 191.0 ± 12.5; p < 0.03).

Suppository is a suitable approach for UP patients. Topical treatment with sulphasalazine (SASP), 5-aminosalicylic acid (5-ASA; the active moiety of SASP), and hydrocortisone has demonstrated its efficiency for active UP patients when they are formulated as suppositories [4–6]. However, some patients have revealed a strong resistance to these current topical therapies because of insufficient clinical improvements and/or adverse side effects. SXS might have the potential to be an adjunct therapeutic option for UP patients with such past episode(s). Fragmental facts have recognized that XS has the potential to have an effect in UC not only in China, but also in Japan [7]. Ohu et al. [8] have proven that XS maintained the gastric mucosal blood flow in chemically induced gastric ulcer models in mice. In this way of thinking, active UP patients should be the best candidates for SXS because it takes effect directly at the disease focus. Clinical symptoms seen in active UP are sometimes similar to UC patients with more expanded colitis. Symptoms such as frequent bloody diarrhea, abdominal pain, and weight loss and consequently chronic recurrent inflammation within the recto-sigmoidal mucosa might initiate serious damage to their QoL. In conclusion, we report here the results of our pilot clinical trial of a suppository-formed Chinese traditional medicine, Xilei-san, for active UP patients. SXS was found to suppress the prevailing inflammation during the 180-day trial with a striking effect on both CAI and EI. Further studies in large cohorts of patients are warranted to evaluate its therapeutic effect and mechanism, and a randomized, controlled, double-blind placebo study has been commenced based upon the results obtained from this pilot trial.

References